US DoD awards CMO Paragon Bioservices $15m vaccine deal

By Nick Taylor

- Last updated on GMT

US DoD awards CMO Paragon Bioservices $15m vaccine deal

Related tags Vaccine

CMO Paragon Bioservices has won a $15m DoD contract to develop a large-scale mammalian process for a trivalent filovirus vaccine.

The US Department of Defense (DoD) expects the $15m (€12m) ‘cost-plus-incentive-fee contract’ to be completed in 2020. By then Maryland, US-based Paragon Bioservices should have performed vaccine development and GMP (good manufacturing practice) production of the treatment.

It doesn't get any better than this for a CMO (contract manufacturing organisation)​”, Marco Chacon, CEO of Paragon Bioservices said. To perform the work Paragon Bioservices will combine its virus-like particle (VLP) production and purification experience with expertise at Harrisvaccines and academia.

Paragon Bioservices competed against three other bids to win the contract. During the first phase of the deal Paragon Bioservices is due to receive $15m and this could more than double if optional contract line item numbers are exercised.

The contract focuses on the Venezuelan equine encephalitis (VEE) replicon particle trivalent filovirus vaccine. Development of the vaccine will give the DoD a tool to fight filoviruses, a potential agent of bioterrorism with a fatality rate of up to 90 per cent.

Filovirus threat

Awarding the contract to Paragon Bioservices is part of a longstanding effort at the DoD to protect the US against filoviruses. In 2005 the DoD awarded Apath $70,000 for filovirus drug discovery using novel combinations of approved compounds and has continued to drive vaccine development.

Paragon Bioservices is already working with filovirus vaccine candidates under another deal with the DoD. Having inked the deal in 2010 Paragon Bioservices has worked on process development and scale-up production of filovirus vaccine candidates with efficacy against Ebola and Marburg viruses.

In a document released in 2010​ the Chemical Biological Medical Systems-Joint Vaccine Acquisition Program, which is leading the filovirus project, said it hopes to have a product ready by fiscal 2024.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Webinars